ClinicalTrials.gg
CompletedNCT05436834Updated Nov 26, 2025

A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

A Phase 3 interventional study of mRNA-1273.214 and mRNA-1273.815 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 74 sites in 7 countries. Open to participants aged 6 Months to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,807
Allocation
Non-randomized
Ages
6 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..

Enrollment
9th of 22
1,807 · median 988
Started
2022
with 8 others
Phase 3
6 of 34
none open now
Registered
14th of 34
by date

Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 9th largest by enrollment of the 22 interventional ones that give a count, is one of 9 that started in 2022, is one of 6 in phase 3, and was the 14th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 6 Months to 5 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in COVID-19 by Moderna, Inc., or all of them as a file.
02

Study summary

This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of the mRNA-1273.815 vaccine, when administered as a BD in participants aged 6 months to \<6 years (Part 3) and when administered to SARS-CoV-2 vaccine-naïve participants aged 2 years to \<5 years of age (Part 4).

Read the detailed description

Part 1 will enroll participants aged 6 months to \<6 years who have not been previously vaccinated against SARS-CoV-2. Participants will receive 2 doses of the mRNA-1273.214 vaccine.

Part 2 will enroll participants aged 6 months to \<6 years who have previously been vaccinated with a mRNA-1273 primary series in Study mRNA-1273-P204 (NCT04796896). Participants will receive a single BD of the mRNA-1273.214 vaccine, at least 4 months after completion of the mRNA-1273 primary series.

Part 3 will enroll participants aged 6 months to \<6 years who have previously been vaccinated with an authorized/approved COVID-19 vaccine. Participants will receive a BD of the mRNA-1273.815 vaccine at least 4 months after the last receipt of a COVID-19 vaccine.

Part 4 will evaluate mRNA-1273.815 vaccine administered as a single dose to SARS-CoV-2 vaccine-naïve participants aged 2 years to \<5 years of age enrolled in Cohort A (Part 4A), compared to 2 doses given to SARS-CoV-2 vaccine-naïve participants aged 6 months to \<2 years enrolled in Cohort B (Part 4B).

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • Coronavirus disease 2019
  • COVID-19
04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • The participant is 6 months to \<6 years for Parts 1, 2, and 3; 2 years to \<5 years for Part 4A; and 6 months to \<2 years for Part 4B at the time of consent (Screening Visit). Note: for Part 1, participant must be at least 6 months old and must not have reached 6 years of age at the time of administration of first dose. For Part 4B, the participant must be at least 6 months old and must not have reached 2 years of age at the time of administration of first dose.
  • If the participant has a chronic disease (that is, asthma, diabetes mellitus, cystic fibrosis, [HIV] infection), the disease should be stable, per investigator assessment, so that the participant can be considered eligible for inclusion. Stable diseases are those which have had no change in their status or in the medications required to control them in the 6 months prior to Screening Visit. Note: a change in medication for dose optimization (that is, insulin dose changes, adjustments for age-related weight gain), change within class of medication, or reduction in dose are not considered signs of instability.
  • In the investigator's opinion, the parent(s)/legally authorized representative(s) (LAR[s]) understand and are willing and physically able to comply with protocol-mandated follow-up, including all procedures and provide written .
  • The participant is 2 years or older and has a (BMI) at or above the second percentile according to World Health Organization (WHO) Child Growth Standards at the Screening Visit.

OR

  • The participant is less than 2 years of age and the participant's height and weight are both at or above the second percentile according to WHO Child Growth Standards at the Screening Visit.

Special inclusion criteria for participants aged 6 months to \< 12 months:

  • The participant was born at full-term (≥ 37 weeks gestation) with a minimum birth weight of 2.5 kilograms (kg).

Inclusion criteria for Part 2:

  • The participant must have received 2 doses of mRNA-1273, approximately 28 to 35 days apart, as 25-μg primary series, and second dose was given at least 4 months prior to enrollment.

Inclusion criteria for Part 3 only:

- The participant must have received an age-appropriate immunization series of an authorized/approved COVID-19 vaccine, with the last dose given at least 4 months prior to enrolment (Previous vaccines NOT allowed are: XBB.1.5-containing formulation).

Exclusion Criteria:

  • Has a known history of SARS-CoV-2 infection (that is, reported AE of COVID-19 or asymptomatic SARS-CoV-2 infection during Study mRNA-1273-P204 at the time of rollover into mRNA-1273-P306 or during Part 1 at the time of rollover into Part 3) in the 90 days prior to dosing in this study.
  • Is acutely ill or febrile 24 hours prior to or at the Screening Visit. Fever is defined as a body temperature ≥ 38.0°Celsius (C)/≥ 100.4°Fahrenheit (F). Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
  • For Parts 1 and 4, participant has previously been administered an or approved CoV (that is, SARS-CoV-2, SARS-CoV, Middle East respiratory syndrome coronavirus [MERS-CoV]) vaccine. For Part 2, participant who received any approved/investigational CoV vaccine are ineligible to participate except for those who received mRNA-1273 (prototype) vaccine.
  • Has undergone treatment with investigational or approved agents for prophylaxis against COVID-19 (including receipt of SARS-CoV-2 monoclonal antibodies for prophylaxis or treatment) within 90 days prior to enrollment.
  • Has a known to a component of the vaccine or its . Hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol [PEG] or immediate allergic reaction of any severity to polysorbate).
  • Has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results.
  • Has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following:

    • Congenital or acquired immunodeficiency, other than well-controlled HIV infection.
    • Chronic hepatitis or suspected active hepatitis
    • A bleeding disorder that is considered a to IM injection or phlebotomy
    • Dermatologic conditions that could affect local solicited AR assessments
    • Any prior diagnosis of (excluding nonmelanoma skin cancer)
  • Has received the following:

    • Any routine vaccination with inactivated or (s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination.

Note: This excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. If a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (eCRF).

  • Systemic or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for , ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs >10 kg). Participants may have visits rescheduled for enrollment if they no longer meet this criterion within the Screening Visit window. Inhaled, nasal, and topical steroids, and palivizumab are allowed.
  • Intravenous (IV) or subcutaneous (SC) blood products (red cells, , immunoglobulins) within 3 months prior to enrollment.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,807 participants (actual)

Study arms

  • Experimental
    mRNA-1273.214 (Part 1)

    Participants who have not been previously vaccinated against SARS-CoV-2, will receive 2 intramuscular (IM) injections of mRNA-1273.214 vaccine on Day 1 and Day 29.

    Biological: mRNA-1273.214

  • Experimental
    mRNA-1273.214 (Part 2)

    Participants who have previously been vaccinated with a mRNA-1273 primary series, will receive a single IM BD of mRNA-1273.214 vaccine at least 4 months after completion of the mRNA-1273 primary series.

    Biological: mRNA-1273.214

  • Experimental
    mRNA-1273.815 (Part 3)

    Participants who have previously been vaccinated with an authorized/approved COVID-19 vaccine, will receive a single IM BD of mRNA-1273.815 vaccine on BD Day 1, at least 4 months after the last dose of a COVID-19 vaccine.

    Biological: mRNA-1273.815

  • Experimental
    mRNA-1273.815 (Part 4)

    Participants in Part 4 Cohort A will receive a single IM injection of mRNA-1273.815 vaccine on Day 1. Participants in Part 4 Cohort B will receive IM injections of mRNA-1273.815 vaccine on Day 1 and Day 29.

    Biological: mRNA-1273.815

Interventions

  • BiologicalmRNA-1273.214

    Sterile liquid for injection

  • BiologicalmRNA-1273.815

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Up to Day 8 (7 days post-vaccination)

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Up to Day 29 (28 days after each injection)

  3. Number of Participants with Medically-Attended AEs (MAAEs)

    Time frame: Up to Day 394 (12 months after last dose)

  4. Number of Participants with Serious AEs (SAEs)

    Time frame: Up to Day 394 (12 months after last dose)

  5. Number of Participants with Adverse Events of Special Interest (AESI)

    Time frame: Up to Day 394 (12 months after last dose)

  6. Number of Participants with AEs Leading to Withdrawal

    Time frame: Up to Day 394 (12 months after last dose)

  7. Geometric Mean (GM) of the Serum Antibody (Ab) Level against Omicron BA.1 and Ancestral SARS-CoV-2 after mRNA-1273.214 Administration at Day 57

    Time frame: Day 57

  8. GM of the Serum Ab Level against Omicron BA.1 and Ancestral SARS-CoV-2 after mRNA-1273.214 Administration at Day 29

    Time frame: Day 29

  9. Seroresponse Rate (SRR) against Omicron BA.1 and Ancestral SARS-CoV-2 after mRNA-1273.214 Administration

    Time frame: Day 29

  10. GM of the Serum Ab Level against Omicron XBB.1.5 after mRNA-1273.815 Administration

    Time frame: Up to Day 57

Secondary outcomes

  1. SRR against Omicron BA.1 and Ancestral SARS-CoV-2 after mRNA-1273.214 Administration Regardless of prior SARS-CoV-2 Infection

    Time frame: Day 57

  2. GM of the Serum Ab Level against Omicron XBB.1.5 after mRNA-1273.815 Administration Regardless of prior SARS-CoV-2 Infection

    Time frame: Up to Day 57

  3. SRR against Omicron XBB.1.5 after mRNA-1273.815 Administration Regardless of prior SARS-CoV-2 Infection

    Time frame: Up to Day 57

07

Study locations

74 sites
  • Trinity Clinical Research, LLC
    Bessemer, Alabama 34020, United States
  • Velcocity Clinical Research
    Banning, California 92220, United States
  • Sera Collection Research Services
    Montebello, California 90640, United States
  • Center For Clinical Trials LLC -Paramount
    Paramount, California 90723, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Meridian Clinical Research
    Washington D.C., District of Columbia 20016, United States
  • Prohealth Research Center
    Doral, Florida 33166, United States
  • University of Florida Jacksonville
    Jacksonville, Florida 32209, United States
  • Kissimmee Clinical Research
    Kissimmee, Florida 34741, United States
  • Med-Care Research
    Miami, Florida 33125, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • IResearch
    Decatur, Georgia 30030, United States
  • Meridian Clinical Research
    Macon, Georgia 31210, United States
  • Velcocity Clinical Research
    Meridian, Idaho 83642, United States
  • Lurie Childrens Hospital
    Chicago, Illinois 60611, United States
  • Meridian Clinical Research
    Overland Park, Kansas 66210, United States
  • Michael W. Simon MD, PSC
    Lexington, Kentucky 40517, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Velocity Clinical Research - Lafayette - PPDS
    Lafayette, Louisiana 70508, United States
  • MedPharmics
    Metairie, Louisiana 70006, United States
  • Velocity Clinical Research - Covington - PPDS
    Metairie, Louisiana 70006, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • University of Missouri Health Care
    Columbia, Missouri 65212, United States
  • Meridian Clinical Research
    Hastings, Nebraska 68901, United States
  • Meridian Clinical Research
    Lincoln, Nebraska 68510, United States
  • Be Well Clinical Studies, LLC - Lincoln - ERN - PPDS
    Lincoln, Nebraska 68516, United States
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
  • Velocity Clinical Research
    Albuquerque, New Mexico 87102, United States
  • Meridian Clinical Research
    Binghamton, New York 13901, United States
  • WellNow Urgent Care Clinical Research
    East Amherst, New York 14051, United States
  • Child Healthcare Associates - East Syracuse
    East Syracuse, New York 13057, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Velcocity Clinical Research
    East Greenwich, Rhode Island 02818, United States
  • Coastal Pediatric Associates
    Charleston, South Carolina 29414, United States
  • Meridian Clinical Research
    Charleston, South Carolina 29414, United States
  • MUSC
    Charleston, South Carolina 29425, United States
  • Le Bonheur Childrens Hospital
    Memphis, Tennessee 38105, United States
  • Velocity Clinical Research Austin
    Austin, Texas 78759, United States
  • REX Clinical Trials, LLC Beaumont
    Beaumont, Texas 77701-3739, United States
  • Velcocity Clinical Research
    Cedar Park, Texas 78613, United States
  • BRCR Global Texas
    Edinburg, Texas 78539, United States
  • Village Health Partners - Frisco Medical Village
    Frisco, Texas 75033, United States
  • Ventavia Research Group
    Houston, Texas 77008, United States
  • Cyfair Clinical Reseach Center
    Houston, Texas 77065, United States
  • Texas Center for Drug Development
    Houston, Texas 77081, United States
  • Victoria Clinical Research Group
    Victoria, Texas 77901, United States
  • PI Coor Clinical Research LLC
    Burke, Virginia 22015, United States
  • Clinical Research Partners
    Richmond, Virginia 23226, United States
  • AES - AS - Glenny Corp. S.A. Buenos Aires
    CABA, Buenos Aires F.D. C1430CKE, Argentina
  • Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich
    Buenos Aires, Ciudad Autónoma de BuenosAires C1426BOS, Argentina
  • AES - AS - Clinica Mayo de Urgencias
    San Miguel de Tucumán, Tucumán Province T4000CAM, Argentina
  • Consultorios Médicos Dr. Doreski - PPDS
    Buenos Aires, C1426ABP, Argentina
  • Centro de Estudios Clinicos e Investigaciones Medicas (CECIM)
    Santiago, Santiago Metropolitan 8320000, Chile
  • AES - AS - Centro de Investigación Clínica CIC S.A.S (CECIC) Medellín
    Medellín, Antioquia 050021, Colombia
  • Clínica de Costa S.A.S
    Barranquilla, Atlántico 80020, Colombia
  • AES- AS- Solano & Terront Servicios Médicos LTDA (UNIENDO) Bogotá
    Bogotá, Bogota D.C. 110221, Colombia
  • Centro de Atencion e Investigacion Medica S.A.S. - CAIMED Aguazul
    Aguazul, Casanare Department 856010, Colombia
  • Centro de Atencion e Investigacion Medica S.A - Yopal - CAIMED
    Yopal, Casanare Department 850001, Colombia
  • Policlínico Social del Norte
    Bogotá, Cundinamarca 110131, Colombia
  • Clínica de la Costa S.A.S- Sede Cartagena
    Cartagena, Departamento de Bolívar 130011, Colombia
  • Centro de Atención e Investigación Médica S.A.S.- CAIMED - S.A.S. Sede Acacias
    Acacías, Meta Department 507001, Colombia
  • Caimed Dominicana S.A.S - CAIMED - PPDS
    Santo Domingo, Distrito NacionalSanto Domingo 11903, Dominican Republic
  • Registrum- La Altagracia
    Salvaleón de Higüey, La Altagracia Province 23000, Dominican Republic
  • Hospital Materno Infantil San Lorenzo de Los Mina
    Santo Domingo Este, Santo Domingo Province 11901, Dominican Republic
  • Hospital General Regional Dr. Marcelino Velez Santana
    Santo Domingo Iesta, Santo Domingo Province 11117, Dominican Republic
  • Unidad de Vacunas e Investigación Instituto Dermatologico Dominicano y Cirugía de Piel Dr. Huberto B
    Santo Domingo, 10305, Dominican Republic
  • CAENSA Clinical Trial
    Panama City, Panama
  • Centro De Vacunacion Internacional, S.A. - David - Cevaxin - PPDS
    Panama City, Panama
  • CEVAXIN 24 de diciembre - PPDS
    Panama City, Panama
  • CEVAXIN Avenida México - PPDS
    Panama City, Panama
  • CEVAXIN Chorrera - PPDS
    Panama City, Panama
  • Curaex Clinical Trial
    Panama City, Panama
  • Instituto de Investigaciones Científicas y Servicios de Alta Tecnología Asociación de Interés Panama
    Panama City, Panama
  • Caribbean Medical Research Center
    San Juan, 00918, Puerto Rico
08

References and documents

Publications

  • Dixit A, Bennett R, Ali K, Griffin C, Clifford RA, Turner M, Poston R, Hautzinger K, Yeakey A, Girard B, Zhou W, Deng W, Zhou H, Schnyder Ghamloush S, Kuter BJ, Slobod K, Miller JM, Priddy F, Das R; ROVER Study Investigators. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial. Lancet Infect Dis. 2024 Jul;24(7):687-697. doi: 10.1016/S1473-3099(24)00101-4. Epub 2024 Mar 19. PubMed 38518789 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Oct 2025, 39 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 39 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jun 29, 2022
StartActual
Jun 21, 2022
Primary completionActual
Oct 20, 2025
CompletionActual
Oct 20, 2025
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05436834
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Jun 29, 2022
Start date
Jun 21, 2022
Primary completion
Oct 20, 2025
Completion
Oct 20, 2025
Last update
Nov 26, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1273.214 COVID-19 vaccine

Start the discussion